title: METALLOPROTEINS DURING DEVELOPMENT OF WALKER-256 CARCINOSARCOMA RESISTANT PHENOTYPE.
abstract: The study was focused on the detection of changes in serum and tumor metal-containing proteins in animals during development ofdoxorubicin-resistant phenotype in malignant cells after 12 courses of chemotherapy. We found that on every stage of resistance development there was a significant increase in content of ferritin and transferrin proteins (which take part in iron traffick and storage) in Walker-256 carc'inosarcoma tissue. We observed decreased serumferritin levels at the beginning stage of the resistance development and significant elevation of this protein levels in the cases withfully developed resistance phenotype. Transferrin content showed changes opposite to that offerritin. During the development of resistance phenotype the tumor tissue also exhibited increased 'free iron' concentration that putatively correlate with elevation of ROS generation and levels of MMP-2 and MMP-9 active forms. The tumor non-protein thiol content increases gradually as well. The serum of animals with early stages of resistance phenotype development showed high ceruloplasmin activity and its significant reduction after loss of tumor sensitivity to doxorubicin. Therefore, the development of resistance phenotype in Walker-256 carcinosarcoma is accompanied by both the deregulation of metal-containing proteins in serum and tumor tissue and by the changes in activity of antioxidant defense system. Thus, the results of this study allow us to determine the spectrum of metal-containing proteins that are involved in the development of resistant tumor phenotype and that may be targeted for methods for doxorubicin sensitivity correction therapy.
authors.forename: V F
authors.initials: VF
authors.lastname: Chekhun
authors.forename: Yu V
authors.initials: YV
authors.lastname: Lozovska
authors.forename: A P
authors.initials: AP
authors.lastname: Burlaka
authors.forename: I I
authors.initials: II
authors.lastname: Ganusevich
authors.forename: Yu V
authors.initials: YV
authors.lastname: Shvets
authors.forename: N Yu
authors.initials: NY
authors.lastname: Lukianova
authors.forename: I M
authors.initials: IM
authors.lastname: Todor
authors.forename: D V
authors.initials: DV
authors.lastname: Demash
authors.forename: A A
authors.initials: AA
authors.lastname: Pavlova
authors.forename: L A
authors.initials: LA
authors.lastname: Naleskina
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D002279:Carcinoma 256, Walker / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D002570:Ceruloplasmin / Q000235:genetics / Q000378:metabolism*; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D005293:Ferritins / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression; D007274:Injections, Intraperitoneal; D007501:Iron / Q000378:metabolism; D008321:Mammary Glands, Animal / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D020778:Matrix Metalloproteinase 2 / Q000235:genetics / Q000378:metabolism*; D020780:Matrix Metalloproteinase 9 / Q000235:genetics / Q000378:metabolism*; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D014168:Transferrin / Q000235:genetics / Q000378:metabolism*
chemical_list: D000903:Antibiotics, Antineoplastic; D017382:Reactive Oxygen Species; D014168:Transferrin; D004317:Doxorubicin; D005293:Ferritins; D007501:Iron; D002570:Ceruloplasmin; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9